Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 10월 2023 - 5:50AM
Business Wire
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company
committed to advancing new medicines for patients with cancer,
today announced the grant of stock options to purchase 60,000
shares of its common stock to one new employee. The awards were
granted pursuant to the Nasdaq inducement grant exception as an
inducement material to the employee's acceptance of employment with
Verastem Oncology in accordance with Nasdaq Listing Rule
5635(c)(4). The stock options have an exercise price equal to $7.65
per share, the closing price of Verastem Oncology’s common stock as
reported by Nasdaq on October 12, 2023. The stock options to
purchase 30,000 shares of common stock that were granted to the one
new employee will vest at a rate of twenty-five percent (25%) on
the one-year anniversary of the employee’s date of hire, with the
remaining shares vesting quarterly over the next three (3) years in
equal quarterly amounts, provided the employee continues to serve
as an employee of or other service provider to Verastem Oncology on
each such vesting date. The stock options to purchase 30,000 shares
of common stock that were granted to one new employee will vest
upon the achievement of a certain commercial milestone, provided
the employee continues to serve as an employee of or other service
provider to Verastem Oncology on such vesting date.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a
development-stage biopharmaceutical company committed to the
development and commercialization of new medicines to improve the
lives of patients diagnosed with cancer. Our pipeline is focused on
novel small molecule drugs that inhibit critical signaling pathways
in cancer that promote cancer cell survival and tumor growth,
including RAF/MEK inhibition and FAK inhibition. For more
information, please visit www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231018337292/en/
Investors:
Dan Calkins Investor Relations +1 781-469-1694
dcalkins@verastem.com
Ryan Porter +1 212-600-1902 ryan.porter@argotpartners.com
Media:
Lisa Buffington Corporate Communications +1 781-292-4502
lbuffington@verastem.com
Verastem (NASDAQ:VSTM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Verastem (NASDAQ:VSTM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024